3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Interventions
Oxaliplatin
53
Cisplatin
52
Fluorouracil
50
Capecitabine
48
pembrolizumab
39
Leucovorin
31
Docetaxel
26
Trastuzumab
23
Paclitaxel
20
Irinotecan
20
Ramucirumab
13
Bevacizumab
12
Cetuximab
9
Radiotherapy
8
Surgical Procedures, Operative
7
S 1 (combination)
7
Nivolumab
7
Epirubicin
7
Carboplatin
6
olaparib
5
Platinum
5
Everolimus
5
Sunitinib
4
Mitomycin
4
trastuzumab deruxtecan
3
lenvatinib
3
epacadostat
3
bemarituzumab
3
apatinib
3
Saline Solution
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Stomach Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts